EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS IN COMBINATION WITH AN AKT INHIBITOR FOR THE TREATMENT OF CANCER

Abstract: the specification relates to epidermal growth factor receptor (egfr) tyrosine kinase inhibitors (tkis) for use in the treatment of cancer, wherein the egfr tki is administered in combination with an akt inhibitor.

Inventor(s): Nicolas FLOCH, Matthew Joseph MARTIN, Paul David SMITH, Ursula GRAZINI

CPC Classification: A61K31/506 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms ; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles ; soap compositions ))

Search for rejections for patent application number 20250205233